Ex Parte Turner et al - Page 14


              Appeal No. 2004-1040                                                        Page 14                        
              Application No. 09/770,643                                                                                 

              disclose any biological processes that have been associated with casprs and, more                          
              specifically, the specification provides no information regarding what biological functions                
              or activities involve the polypeptides encoded by the instantly claimed nucleic acids.                     
                     Nor have Appellants provided other evidence to show that the biological activity                    
              or role of the protein of SEQ ID NO:2 would have been apparent to those skilled in the                     
              art at the time this application was filed.4  The only prior art cited by Appellants that                  
              bears on the activity of caspr proteins is Poliak,5 of which only the abstract is of record.               
              Poliak discloses that the protein Caspr2 is found in a particular part (the “juxtaparanodal                
              region”) of nerve cells (myelinated axons) and suggests that Caspr family members may                      
              have a role in “the local differentiation of the axon into distinct functional subdomains.”                
              Appellants have provided no explanation of how Poliak’s disclosure would have                              
              suggested a well-established utility for other caspr proteins to those skilled in the art,                 
              and no such utility is apparent to us.                                                                     
                     Appellants argue that the examiner “admit[ted] that casprs have a specific utility,                 
              due to their association with ‘myelinated axons and potassium channels,’” citing the                       
              Final Action (Paper No. 14) at page 3.  We have reviewed the Final Action and do not                       
              find that the examiner has admitted that the instantly claimed invention has utility.                      




                                                                                                                         
              4 Whether a claimed invention is supported by a disclosure of utility sufficient to satisfy 35 U.S.C. § 101 is
              determined as of the filing date of the application.  See In re Brana, 51 F.3d 1560, 1566 n.19, 34 USPQ2d  
              1436, 1441 n.19 (Fed. Cir. 1995) (“Enablement, or utility, is determined as of the application filing date.”).
              Therefore, we have not considered any of the references cited by the examiner or by Appellants that were   
              published after the effective filing date of the present application.                                      
              5 Poliak et al., “Caspr2, a new member of the neurexin superfamily, is localized at the juxtaparanodes of  
              myelinated axons and associates with K+ channels,” Neuron, Vol. 24, pp. 1037-1047 (1999).                  





Page:  Previous  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  Next 

Last modified: November 3, 2007